![Kanad D. Das](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kanad D. Das
Directeur/Membre du Conseil chez
Oncomyx Therapeutics, Inc.
Profil
Kanad D.
Das has worked as an Investment Director at Boehringer Ingelheim (Venture Capital) since 2018.
He also currently holds Director positions at Actym Therapeutics, Inc. and Oncomyx Therapeutics, Inc.
Postes actifs de Kanad D. Das
| Sociétés | Poste | Début |
|---|---|---|
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Develops and operates software platform to orchestrate an immune response & treat cancer | Directeur/Membre du Conseil | - |
Actym Therapeutics, Inc.
 Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immune-oncology therapies | Directeur/Membre du Conseil | - |
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Private Equity Investor | 01/05/2018 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
41
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Finance |
Actym Therapeutics, Inc.
Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immune-oncology therapies | Health Technology |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Develops and operates software platform to orchestrate an immune response & treat cancer | Technology Services |
